FIG 3.

The NHC inhibition profile of MHV is consistent with mutagenesis. (A) Treatment with 16 μM NHC (∼100 times the EC₅₀) significantly inhibits MHV replication during a single infection when added before 6 h p.i. (B) Both MHV titer and monolayer RNA copies decrease after treatment with increasing concentrations of NHC. (C) NHC treatment results in a decrease in supernatant MHV RNA. (D) Data from panel C represented as the ratio of infectious WT MHV to genomic MHV RNA present in the supernatant, or specific infectivity, normalized to that of vehicle control. NHC treatment resulted in a decrease in the specific infectivity of MHV. All the data represent the results of 2 independent experiments, each with 3 replicates. The error bars represent SEM. Statistical significance compared to DMSO control was determined by one-way analysis of variance (ANOVA) with Dunnett’s post hoc test for multiple comparisons. *, P < 0.05; **; P < 0.01; ***, P < 0.001; ****, P < 0.0001.